KamadaKMDA
About: Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Employees: 374
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
511% more call options, than puts
Call options by funds: $110K | Put options by funds: $18K
52% more funds holding
Funds holding: 23 [Q4 2024] → 35 (+12) [Q1 2025]
1.66% less ownership
Funds ownership: 10.63% [Q4 2024] → 8.97% (-1.66%) [Q1 2025]
7% less capital invested
Capital invested by funds: $37.2M [Q4 2024] → $34.4M (-$2.73M) [Q1 2025]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Benchmark Robert Wasserman | 118%upside $15 | Buy Reiterated | 15 May 2025 |
Financial journalist opinion
Based on 5 articles about KMDA published over the past 30 days
